Since September 2010, scholars have been focusing on the clinical study on EGFR-TKI retreatment after chemotherapy when NSCLC patients acquired drug resistance in the advanced stages of the initial EGFR-TKI treatment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.